MCID: FBR017
MIFTS: 55

Fibrosarcoma

Categories: Bone diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Fibrosarcoma

MalaCards integrated aliases for Fibrosarcoma:

Name: Fibrosarcoma 12 73 20 58 29 54 44 15 17 70
Neoplasms, Fibrous Tissue 44 70
Fibrosarcoma of Soft Tissue 12
Fibrous Tissue Neoplasm 12
Fibrocytic Tumor 12

Characteristics:

Orphanet epidemiological data:

58
fibrosarcoma
Prevalence: <1/1000000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:3355
SNOMED-CT 67 443250000
MESH via Orphanet 45 D005354
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 71 C0016057
Orphanet 58 ORPHA2030
UMLS 70 C0016057 C0206643 C1336021

Summaries for Fibrosarcoma

Disease Ontology : 12 A connective tissue cancer that has material basis in fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern.

MalaCards based summary : Fibrosarcoma, also known as neoplasms, fibrous tissue, is related to congenital fibrosarcoma and adult fibrosarcoma. An important gene associated with Fibrosarcoma is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Degradation of the extracellular matrix. The drugs Doxorubicin and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include endothelial, skin and bone, and related phenotypes are Reduced mammosphere formation and shRNA abundance <= 50%

Wikipedia : 73 Fibrosarcoma (fibroblastic sarcoma) is a malignant mesenchymal tumour derived from fibrous connective... more...

Related Diseases for Fibrosarcoma

Diseases in the Fibrosarcoma family:

Adult Fibrosarcoma Congenital Fibrosarcoma

Diseases related to Fibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 531)
# Related Disease Score Top Affiliating Genes
1 congenital fibrosarcoma 32.9 VIM NTRK3 ETV6
2 adult fibrosarcoma 32.6 NTRK3 ETV6
3 infantile myofibromatosis 32.3 VIM NTRK3 ETV6
4 spindle cell sarcoma 31.4 VIM NTRK3 ETV6
5 nephroma 31.1 VIM NTRK3 ETV6
6 osteogenic sarcoma 31.0 TNF MMP9 MMP2 MALAT1 JUN
7 fasciitis 31.0 VIM TNF ETV6
8 breast adenocarcinoma 30.8 TNF SERPINE1 PLAU MMP9 MMP2
9 cellular congenital mesoblastic nephroma 30.6 NTRK3 ETV6
10 aortic aneurysm, familial abdominal, 1 30.6 TNF TIMP2 TIMP1 SERPINE1 PLAU MMP9
11 pneumothorax 30.5 VIM TIMP2 TIMP1 MMP9 MMP2
12 corneal ulcer 30.3 MMP9 MMP2 FN1
13 aortic aneurysm, familial thoracic 1 30.3 TIMP2 TIMP1 MMP9 MMP2
14 periodontitis 30.3 TNF TIMP1 MMP9 MMP2
15 breast secretory carcinoma 30.3 NTRK3 ETV6
16 anaplastic astrocytoma 30.3 TIMP2 PLAU MMP9 MMP2
17 retinal detachment 30.3 TNF TIMP1 MMP9 MMP2
18 arthritis 30.2 TNF TIMP1 MMP9 MMP14 JUN
19 disseminated intravascular coagulation 30.2 TNF SERPINE1 FN1
20 varicose veins 30.2 TNF TIMP2 TIMP1 MMP9 MMP2 FN1
21 hemorrhagic disease 30.2 TNF SERPINE1 FN1 ETV6
22 gastrointestinal stromal tumor 30.1 VIM NTRK3 MMP9 MMP2
23 cystitis 30.1 VIM TNF JUN
24 liver cirrhosis 30.0 TNF TIMP2 TIMP1 MMP2 MALAT1
25 melanoma 30.0 VIM TNF TIMP2 TIMP1 PLAU MMP9
26 renal cell carcinoma, nonpapillary 30.0 VIM TIMP2 MMP9 MMP2 MALAT1 JUN
27 high grade glioma 29.8 TNF TIMP2 MMP9 MMP2 MALAT1
28 lung cancer susceptibility 3 29.8 PLAU MMP9 MMP2 MALAT1 JUN
29 bladder cancer 29.7 TNF TIMP2 PLAU MMP9 MMP2 MALAT1
30 neuroblastoma 29.7 TNF NTRK3 MMP9 MMP2 MALAT1 JUN
31 small bowel fibrosarcoma 11.3
32 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.3
33 liver fibrosarcoma 11.3
34 heart fibrosarcoma 11.3
35 breast fibrosarcoma 11.2
36 kidney fibrosarcoma 11.2
37 central nervous system fibrosarcoma 11.2
38 conventional fibrosarcoma 11.2
39 fibrosarcoma of bone 11.1
40 dermatofibrosarcoma protuberans 11.1
41 pediatric fibrosarcoma 11.1
42 fibroma 11.1
43 inflammatory myofibroblastic tumor 11.0
44 chromosome 17q11.2 deletion syndrome 10.9
45 ayme-gripp syndrome 10.6 MAFK MAFG MAF
46 extracranial arteriovenous malformation 10.6 MMP9 MMP2
47 lentigo maligna melanoma 10.6 TIMP1 MMP9 MMP2
48 focal myositis 10.6 MMP9 MMP2
49 light chain deposition disease 10.6 MMP9 MMP2 MMP14
50 amaurosis fugax 10.6 SERPINE1 MMP9

Graphical network of the top 20 diseases related to Fibrosarcoma:



Diseases related to Fibrosarcoma

Symptoms & Phenotypes for Fibrosarcoma

GenomeRNAi Phenotypes related to Fibrosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.5 ETV6 JUN MMP14 MMP2 TIMP1 TIMP2
2 shRNA abundance <= 50% GR00343-S 9.1 JUN MAFB MMP14 MMP2 SERPINE1 TIMP2

MGI Mouse Phenotypes related to Fibrosarcoma:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.48 ETV6 FN1 JUN MAF MAFA MAFB
2 cardiovascular system MP:0005385 10.45 ETV6 FN1 JUN MAF MAFB MMP14
3 hematopoietic system MP:0005397 10.41 ETV6 FN1 JUN MAF MAFG MAFK
4 immune system MP:0005387 10.41 ETV6 FN1 JUN MAF MAFB MAFG
5 behavior/neurological MP:0005386 10.4 JUN MAF MAFB MAFG MAFK MMP14
6 homeostasis/metabolism MP:0005376 10.4 ETV6 FN1 JUN MAF MAFA MAFB
7 mortality/aging MP:0010768 10.36 ETV6 FN1 JUN MAF MAFB MAFG
8 cellular MP:0005384 10.31 ETV6 FN1 JUN MAFB MAFG MAFK
9 nervous system MP:0003631 10.21 FN1 JUN MAF MAFB MAFG MAFK
10 craniofacial MP:0005382 10.16 FN1 JUN MAF MAFB MMP14 MMP2
11 integument MP:0010771 10.15 ETV6 FN1 JUN MAF MMP14 MMP9
12 muscle MP:0005369 10.09 FN1 MAFG MAFK MMP14 MMP2 MMP9
13 normal MP:0002873 10.06 ETV6 FN1 JUN MAFA MAFB MAFF
14 limbs/digits/tail MP:0005371 10.02 FN1 JUN MAF MMP14 MMP9 TIMP1
15 neoplasm MP:0002006 10.01 ETV6 FN1 MMP2 MMP9 PLAU SERPINE1
16 reproductive system MP:0005389 9.96 FN1 MAFB MAFK MMP14 MMP9 NTRK3
17 respiratory system MP:0005388 9.9 JUN MAFB MMP14 MMP2 MMP9 NTRK3
18 skeleton MP:0005390 9.65 FN1 JUN MAFB MMP14 MMP2 MMP9
19 vision/eye MP:0005391 9.28 JUN MAF MMP14 MMP2 MMP9 NTRK3

Drugs & Therapeutics for Fibrosarcoma

Drugs for Fibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
2
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
3
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
4
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
5
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
6
Liposomal doxorubicin Phase 2, Phase 3 31703
7 Antibiotics, Antitubercular Phase 2, Phase 3
8 Alkylating Agents Phase 2, Phase 3
9 Anti-Bacterial Agents Phase 2, Phase 3
10
Isophosphamide mustard Phase 2, Phase 3 100427
11
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
12
Cytarabine Approved, Investigational Phase 1, Phase 2 147-94-4 6253
13
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563
14
Idarubicin Approved Phase 1, Phase 2 58957-92-9 42890
15
Gemcitabine Approved Phase 2 95058-81-4 60750
16
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
17
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
18
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
19
Bevacizumab Approved, Investigational Phase 2 216974-75-3
20
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
21
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
22
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
23
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
24
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
25
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
26
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166 2942
27
Dexrazoxane Approved, Withdrawn Phase 2 24584-09-6 71384
28
Mesna Approved, Investigational Phase 2 3375-50-6 598
29
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
30
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
31
Lenograstim Approved, Investigational Phase 2 135968-09-1
32
Etoposide Approved Phase 2 33419-42-0 36462
33
Dactinomycin Approved, Investigational Phase 2 50-76-0 2019 457193
34
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
35
Saracatinib Investigational Phase 2 379231-04-6
36
Molgramostim Investigational Phase 2 99283-10-0
37 Protein Kinase Inhibitors Phase 1, Phase 2
38 Antimetabolites Phase 1, Phase 2
39 Mitogens Phase 1, Phase 2
40 Antiviral Agents Phase 1, Phase 2
41 Endothelial Growth Factors Phase 1, Phase 2
42 Imatinib Mesylate Phase 2 220127-57-1 123596
43 Immunoglobulins Phase 2
44 Antibodies Phase 2
45 Antibodies, Monoclonal Phase 2
46 Antifungal Agents Phase 2
47 Antineoplastic Agents, Immunological Phase 2
48 Angiogenesis Inhibitors Phase 2
49 Albumin-Bound Paclitaxel Phase 1, Phase 2
50 taxane Phase 1, Phase 2

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Unknown status NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
3 Phase II Study on Axitinib in Advanced VEGFR and/or PDGFR Solitary Fibrous Tumor Unknown status NCT02261207 Phase 2 Axitinib
4 Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006), an Oral Vascular Endothelial Growth Factor (VEGF), Rapidly Accelerated Fibrosarcoma (RAF) and FMS-like Tyrosine Kinase 3 (FLT3), in Patients With High-risk MDS and AML Completed NCT00542971 Phase 1, Phase 2 Idarubicin;Sorafenib;Ara-C
5 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
6 A Phase II Study of Imatinib (NSC-716051) in Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans Completed NCT00084630 Phase 2 imatinib mesylate
7 A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma Completed NCT01532687 Phase 2 Gemcitabine;Gemcitabine Hydrochloride;Pazopanib;Pazopanib Hydrochloride
8 A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
9 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
10 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
11 A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
12 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
13 A Phase 1/2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors. Completed NCT01962103 Phase 1, Phase 2 nab-paclitaxel;nab-paclitaxel
14 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
15 Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
16 ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING) Recruiting NCT03840772 Phase 2 Eribulin
17 Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients Recruiting NCT03023124 Phase 2 Trabectedin;Adriamycin;Dacarbazine
18 Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias Recruiting NCT03834961 Phase 2 Larotrectinib Sulfate
19 A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
20 A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC) Active, not recruiting NCT02066285 Phase 2 Pazopanib
21 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
22 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Active, not recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
23 Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Active, not recruiting NCT03989596 Phase 2
24 A Pilot Phase II Study for Children With Infantile Fibrosarcoma Terminated NCT00072280 Phase 2 cyclophosphamide;etoposide;ifosfamide;vincristine sulfate
25 S9624: Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors Terminated NCT00003292 Phase 2 ifosfamide
26 A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
27 A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma Recruiting NCT04420975 Phase 1 Immunotherapeutic Agent
28 A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas Active, not recruiting NCT03009201 Phase 1 Doxorubicin Hydrochloride;Ribociclib
29 A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies Withdrawn NCT02915172 Phase 1 Lenvatinib;Capecitabine
30 Epidemiology and Outcome of Solitary Fibrous Tumors of the Pleura. A Multicenter Study. Unknown status NCT01694654
31 Observational - Potentially Actionable Mutations in Archived Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) Completed NCT01567046
32 Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group Recruiting NCT03967834
33 Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma Recruiting NCT02613312
34 Staging Procedures to Diagnose Malignant Pleural Mesothelioma Recruiting NCT02648763
35 Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma Recruiting NCT02613299

Search NIH Clinical Center for Fibrosarcoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Dacarbazine

Cochrane evidence based reviews: fibrosarcoma

Genetic Tests for Fibrosarcoma

Genetic tests related to Fibrosarcoma:

# Genetic test Affiliating Genes
1 Fibrosarcoma (disease) 29

Anatomical Context for Fibrosarcoma

MalaCards organs/tissues related to Fibrosarcoma:

40
Endothelial, Skin, Bone, T Cells, Breast, Thyroid, Pituitary

Publications for Fibrosarcoma

Articles related to Fibrosarcoma:

(show top 50) (show all 9930)
# Title Authors PMID Year
1
Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. 61 54
20442303 2010
2
Biosynthesis and recovery of selenium nanoparticles and the effects on matrix metalloproteinase-2 expression. 54 61
20408816 2010
3
TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. 61 54
20406839 2010
4
The human alpha11 integrin promoter drives fibroblast-restricted expression in vivo and is regulated by TGF-beta1 in a Smad- and Sp1-dependent manner. 61 54
19913614 2010
5
The benzoylurea derivative F13 inhibits cell growth, migration and invasion through inducing expression of ERK1/2-mediated RECK in fibrosarcoma HT-1080 cells. 54 61
20051826 2010
6
The role of MT2-MMP in cancer progression. 61 54
20117087 2010
7
Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells. 54 61
19551841 2010
8
Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study. 61 54
19862822 2010
9
Inhibition of the expression on MMP-2, 9 and morphological changes via human fibrosarcoma cell line by 6,6'-bieckol from marine alga Ecklonia cava. 61 54
20132738 2010
10
Identification of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation in association with neuroblastoma progression. 61 54
19961596 2009
11
Regulation of homotypic cell-cell adhesion by branched N-glycosylation of N-cadherin extracellular EC2 and EC3 domains. 61 54
19846557 2009
12
Insulin but not glucagon gene is silenced in human pancreas-derived mesenchymal stem cells. 54 61
19785038 2009
13
VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. 54 61
19910495 2009
14
bFGF induces changes in hyaluronan synthase and hyaluronidase isoform expression and modulates the migration capacity of fibrosarcoma cells. 54 61
19577615 2009
15
Stabilization of anaphase midzone microtubules is regulated by Rho during cytokinesis in human fibrosarcoma cells. 61 54
19576212 2009
16
[Mechanism of endothelial Rho/Rho kinase in extravascular migration of fibrosarcoma cell]. 61 54
19968078 2009
17
PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. 54 61
19342157 2009
18
Identification of integrins alpha6 and beta7 as c-Jun- and transformation-relevant genes in highly invasive fibrosarcoma cells. 54 61
19405119 2009
19
Paeonol exerts anti-angiogenic and anti-metastatic activities through downmodulation of Akt activation and inactivation of matrix metalloproteinases. 61 54
19571375 2009
20
Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. 54 61
19478560 2009
21
The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions. 61 54
19375915 2009
22
A novel mode of cell detachment from fibrillar fibronectin matrix under shear. 54 61
19401337 2009
23
LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor. 54 61
19366727 2009
24
Autotaxin promotes the expression of matrix metalloproteinase-3 via activation of the MAPK cascade in human fibrosarcoma HT-1080 cells. 54 61
19212832 2009
25
Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates. 61 54
19234490 2009
26
[Triptolide evaluates DNA methylation level of matrix metalloproteinase 9 gene in human fibrosarcoma HT-1080 cells]. 61 54
19526795 2009
27
Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA. 61 54
18495463 2009
28
Mapping proteolytic cancer cell-extracellular matrix interfaces. 61 54
18600304 2009
29
Chondroitin sulfate A regulates fibrosarcoma cell adhesion, motility and migration through JNK and tyrosine kinase signaling pathways. 54 61
19368127 2009
30
Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. 54 61
18802920 2008
31
TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. 61 54
19077262 2008
32
Use of the Rad51 promoter for targeted anti-cancer therapy. 61 54
19106292 2008
33
Transcription factors as therapeutic targets for diabetes. 61 54
18851698 2008
34
Glucose regulation of insulin gene expression in pancreatic beta-cells. 54 61
18778246 2008
35
Mapping local matrix remodeling induced by a migrating tumor cell using three-dimensional multiple-particle tracking. 61 54
18641063 2008
36
Flavonoid glycosides isolated from Salicornia herbacea inhibit matrix metalloproteinase in HT1080 cells. 54 61
18715546 2008
37
Plasminogen activator inhibitor-2, but not cystatin C, inhibits the prometastatic activity of tissue inhibitor of metalloproteinases-1 in the liver. 61 54
18681831 2008
38
Wdnm1-like, a new adipokine with a role in MMP-2 activation. 61 54
18492766 2008
39
Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells. 54 61
18627313 2008
40
Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. 61 54
18421307 2008
41
Global and focused transcriptional profiling of small molecule aminopeptidase N inhibitor reveals its mechanism of angiogenesis inhibition. 54 61
18413233 2008
42
Efrapeptin J, a new down-regulator of the molecular chaperone GRP78 from a marine Tolypocladium sp. 54 61
18667784 2008
43
Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. 61 54
18483249 2008
44
Fibronectin fragmentation is a feature of periodontal disease sites and diabetic foot and leg wounds and modifies cell behavior. 54 61
18454665 2008
45
Human tissue factor pathway inhibitor-2 induces caspase-mediated apoptosis in a human fibrosarcoma cell line. 54 61
18401718 2008
46
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. 61 54
18451175 2008
47
A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. 54 61
18392131 2008
48
Anti-cancer effect of bio-reductive drug beta-lapachon is enhanced by activating NQO1 with heat shock. 61 54
18283592 2008
49
Collagen-binding domains of gelatinase A and thrombospondin-derived peptides impede endocytic clearance of active gelatinase A and promote HT1080 fibrosarcoma cell invasion. 61 54
18222489 2008
50
Regulation of hyaluronan and versican deposition by growth factors in fibrosarcoma cell lines. 54 61
17980161 2008

Variations for Fibrosarcoma

Expression for Fibrosarcoma

Search GEO for disease gene expression data for Fibrosarcoma.

Pathways for Fibrosarcoma

Pathways related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 TIMP1 SERPINE1 PLAU MAFK MAFG MAFF
2
Show member pathways
12.67 TIMP2 TIMP1 SERPINE1 MMP9 MMP2 MMP14
3 12.26 TNF PLAU MMP9 MMP2 FN1
4
Show member pathways
12.24 TIMP1 SERPINE1 JUN FN1
5 12.22 PLAU MMP9 MAF ETV6
6 12.12 TNF MMP9 MMP2 MMP14
7 12.04 TNF MMP9 MMP2 JUN
8 11.97 SERPINE1 MMP9 MMP2 MMP14
9 11.93 TNF MMP9 MMP14 JUN
10 11.88 SERPINE1 PLAU MMP14 JUN FN1
11 11.81 TIMP2 TIMP1 MMP9 MMP2
12 11.8 TNF SERPINE1 MMP2 JUN FN1
13 11.79 VIM TNF TIMP1 MMP9 MMP2 FN1
14 11.72 MMP9 MMP2 JUN
15
Show member pathways
11.7 TNF MAF JUN
16 11.66 MMP9 MMP2 MMP14 JUN
17 11.63 MMP9 MMP2 JUN
18
Show member pathways
11.63 TNF TIMP2 TIMP1 MMP9 MMP2 MMP14
19
Show member pathways
11.62 TNF MMP9 MMP2 JUN
20 11.57 TNF SERPINE1 JUN
21 11.57 TNF TIMP1 PLAU MMP9 MMP2
22 11.54 PLAU MMP2 JUN
23 11.49 TNF MMP2 JUN
24 11.45 PLAU MMP9 JUN
25
Show member pathways
11.45 PLAU MMP9 MMP2 JUN
26 11.4 TNF PLAU MMP9 MMP2 FN1
27 11.27 PLAU MMP9 MMP2 JUN
28 11.14 TIMP2 TIMP1 MMP9
29 11.14 MAFK MAFG MAFF MAFB MAFA MAF
30 11.01 TIMP2 TIMP1 SERPINE1 PLAU MMP9 MMP2
31 10.96 VIM TNF TIMP2 TIMP1 NTRK3 JUN
32 10.77 SERPINE1 PLAU

GO Terms for Fibrosarcoma

Cellular components related to Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin GO:0000785 9.91 MAFK MAFF MAFB MAFA MAF JUN
2 extracellular space GO:0005615 9.81 TNF TIMP2 TIMP1 SERPINE1 PLAU MMP9
3 collagen-containing extracellular matrix GO:0062023 9.65 TIMP2 SERPINE1 MMP9 MMP2 FN1
4 platelet alpha granule lumen GO:0031093 9.5 TIMP1 SERPINE1 FN1
5 extracellular matrix GO:0031012 9.43 TIMP2 TIMP1 MMP9 MMP2 MMP14 FN1
6 host cell nucleus GO:0042025 9.17 MAFK MAFG MAFF MAFB MAFA MAF

Biological processes related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 10.15 MAFK MAFG MAFF MAFB MAFA MAF
2 regulation of transcription by RNA polymerase II GO:0006357 10.13 TNF MAFK MAFG MAFF MAFB MAFA
3 positive regulation of gene expression GO:0010628 9.97 VIM TNF NTRK3 MAFG MAF FN1
4 positive regulation of cell migration GO:0030335 9.92 PLAU NTRK3 MMP9 MMP14
5 regulation of cell proliferation GO:0042127 9.91 TNF PLAU MAFG JUN
6 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 TNF SERPINE1 MAFG MAFF MAFB MAFA
7 blood coagulation GO:0007596 9.88 PLAU MAFK MAFG MAFF
8 angiogenesis GO:0001525 9.85 SERPINE1 MMP2 MMP14 JUN FN1
9 cytokine-mediated signaling pathway GO:0019221 9.85 VIM TNF TIMP1 MMP9 MMP2 FN1
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.81 TNF NTRK3 FN1
11 ephrin receptor signaling pathway GO:0048013 9.8 NTRK3 MMP9 MMP2
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.75 TNF MMP2 JUN
13 response to hormone GO:0009725 9.74 TIMP2 TIMP1 MMP14
14 response to cytokine GO:0034097 9.73 TIMP2 TIMP1 JUN
15 response to organic substance GO:0010033 9.73 TNF TIMP2 TIMP1 JUN
16 collagen catabolic process GO:0030574 9.71 MMP9 MMP2 MMP14
17 cellular response to reactive oxygen species GO:0034614 9.69 MMP9 MMP2 JUN
18 response to amyloid-beta GO:1904645 9.64 MMP9 MMP2
19 extracellular matrix organization GO:0030198 9.63 TNF SERPINE1 MMP9 MMP2 MMP14 FN1
20 tissue remodeling GO:0048771 9.62 MMP2 MMP14
21 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.62 TNF MMP9 MMP2 JUN
22 negative regulation of vascular wound healing GO:0061044 9.61 TNF SERPINE1
23 negative regulation of metallopeptidase activity GO:1905049 9.6 TIMP2 TIMP1
24 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.59 TIMP2 TIMP1
25 cellular response to UV-A GO:0071492 9.58 TIMP1 MMP9 MMP2
26 regulation of epidermal cell differentiation GO:0045604 9.52 MAFG MAFF
27 endodermal cell differentiation GO:0035987 9.26 MMP9 MMP2 MMP14 FN1
28 extracellular matrix disassembly GO:0022617 9.02 TIMP2 TIMP1 MMP9 MMP2 MMP14

Molecular functions related to Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.97 MAFK MAFG MAFF MAFB MAFA MAF
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.92 MAFK MAFG MAFF MAFB MAFA MAF
3 sequence-specific double-stranded DNA binding GO:1990837 9.88 MAFG MAFF MAFB MAFA MAF JUN
4 sequence-specific DNA binding GO:0043565 9.73 MAFK MAFF MAFB MAF JUN ETV6
5 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.7 MAFG MAFF MAFB MAFA MAF JUN
6 endopeptidase activity GO:0004175 9.61 MMP9 MMP2 MMP14
7 DNA-binding transcription factor activity GO:0003700 9.56 MAFK MAFG MAFF MAFB MAFA MAF
8 protease binding GO:0002020 9.02 TNF TIMP2 TIMP1 SERPINE1 FN1

Sources for Fibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....